NASDAQ:FLDM
Delisted
Fluidigm Corporation Stock News
$1.83
+0 (+0%)
At Close: Jul 20, 2022
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
11:48am, Tuesday, 05'th Apr 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Theravance Announces Phase 3 Data For Ampreloxetine Showing Clear Benefit In Multiple System Atrophy P
Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.
09:31pm, Monday, 04'th Apr 2022 GlobeNewswire Inc.
New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022
Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion
08:05pm, Friday, 01'st Apr 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today announced that its stockholders have voted to approve all of the proposals related to the pre
Fluidigm Announces Support Agreement with Caligan Partners Related to $250 Million Strategic Capital Infusion by Casdin Capital and Viking Global
01:29pm, Tuesday, 29'th Mar 2022 GlobeNewswire Inc.
Caligan Partners to Vote “FOR” Casdin and Viking Transaction and All Other Fluidigm Proposals at the Special Meeting to be Reconvened on April 1, 2022
Fluidigm Highlights the Strategic Capital Infusion by Casdin Capital and Viking Global as the Only Actionable Financing Solution
12:30pm, Monday, 28'th Mar 2022 GlobeNewswire Inc.
Company Urges ALL Stockholders to Vote “FOR” the Proposals at the Special Meeting
Fluidigm Adjourns Special Meeting of Stockholders Until April 1, 2022
08:00pm, Friday, 25'th Mar 2022 GlobeNewswire Inc.
Provides Stockholders Additional Time to Consider $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors Provides Stockholders Additional Time to Consider $250 Millio
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Fluidigm Stockholders Vote “FOR” ALL Proposals Related to $250 Million Strategic Capital Infusion
09:58pm, Thursday, 17'th Mar 2022 GlobeNewswire Inc.
Fluidigm Board of Directors Unanimously Recommends Stockholders Vote “FOR” ALL Proposals TODAY Fluidigm Board of Directors Unanimously Recommends Stockholders Vote “FOR” ALL Proposals TODAY
Digital PCR (dPCR) and Real-Time PCR (qPCR) Market Worth USD 1180.1 million, Globally, by 2028 at 6.8% CAGR - Exclusive Report by Absolute Reports
06:37am, Friday, 18'th Feb 2022 Benzinga
Pune, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Global Digital PCR (dPCR) and Real-Time PCR (qPCR) Market report delivers a complete overview of key components like drivers, limitations, historic and current trends, technical development, and future growth. Research report contains company analysis, size, share, revenue and sales of the company, current advancements. Digital PCR and Real-Time PCR market analysis also focuses on the global key top industry players in the market, with details such as company profiles, capacity, production, price, cost, revenue. Get a Sample Copy of the Report at - https://www.absolutereports.com/enquiry/request-sample/20190575 The global Digital PCR and Real-Time PCR market size is projected to reach USD 1879.8 million by 2028, from USD 1180.1 million in 2021, at a CAGR of 6.8% during 2022-2028. Polymerase chain reaction (PCR) is a laboratory technique performed commonly to amplify DNA, thereby producing many copies of a particular section of DNA in interest.
Fluidigm Non-GAAP EPS of -$0.01 beats by $0.17, revenue of $38.27M beats by $5.57M
11:01pm, Thursday, 17'th Feb 2022 Seeking Alpha
Fluidigm press release (NASDAQ:FLDM): Q4 Non-GAAP EPS of -$0.01 beats by $0.17.Revenue of $38.27M (-14.2% Y/Y) beats by $5.57M.
Fluidigm Announces Fourth Quarter and Full Year 2021 Financial Results
10:43pm, Thursday, 17'th Feb 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive hea
Fluidigm Announces Fourth Quarter and Full Year 2021 Financial Results
10:43pm, Thursday, 17'th Feb 2022 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced financial results for the fourth quarter and full year ended December 31, 2021.
Fluidigm Files Preliminary Proxy Statement in Connection with Proposed Strategic Capital Infusion from Casdin Capital and Viking Global Investors
11:10am, Monday, 14'th Feb 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today filed with the U.S. Securities and Exchange Commission (the “SEC”) a preliminary proxy sta
Remarkable Stock Buzz: Fluidigm Corporation (NASDAQ:FLDM), Mustang Bio, Inc. (NASDAQ:MBIO)
12:30am, Tuesday, 08'th Feb 2022 Stock Equity
Fluidigm Corporation (NASDAQ:FLDM) with the stream of 4.85% also noticed, India Mustang Bio, Inc. (NASDAQ:MBIO) encountered a rapid change of 0.00% in the last hour of Mondays trading session. Fluidigm The post Remarkable Stock Buzz: Fluidigm Corporation (NASDAQ:FLDM), Mustang Bio, Inc. (NASDAQ:MBIO) appeared first on Stocks Equity .
Worldwide Spatial OMICS Industry to 2028 - Featuring 10x Genomics, NanoString Technologies and PerkinElmer Among Others - ResearchAndMarkets.com
05:49pm, Thursday, 03'rd Feb 2022 Benzinga
The "Global Spatial OMICS Market, By Sample Type, By End Use, By Technology, By Product, By Workflow, Estimation & Forecast, 2018 - 2028" report has been added to ResearchAndMarkets.com''s offering. The global spatial OMICS market held a market value of USD 230.2 million in 2020 and is estimated to reach USD 506.6 million by the year 2028. The market is anticipated to register a CAGR of 10.3% during the forecast period. Companies Mentioned 10x Genomics S2 Genomics, Inc. NanoString Technologies Seven Bridges Genomics PerkinElmer, Inc. Bio-Techne Danaher Corporation IonPath, Inc. Millennium Science Pty Ltd Akoya Biosciences, Inc. Fluidigm Corporation Diagenode Diagnostics Biognosys AG Rebus Biosystems Ultivue, Inc. BioSpyder Technologies Bruker Spatial omics combines the molecular scrutiny with spatial data on the cell''s localization in the interior of the tissue. Omics is a term brief for numerous diverse studies, such as epigenomics, genomics, transcriptomics, lipidomics proteomics, and metabolomics, among others.